Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
DE0006632003
Thu, 17.09.2020
MorphoSys AG
MorphoSys and I-Mab Announce FDA Clearance of IND Application for MOR210/TJ210 in Patients with Advanced Cancer
Phase 1 Clinical Study Expected to Start in Q4 2020
PLANEGG/MUNICH Germany and SHANGHAI, China, September 17, 2020 - MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) and I-Mab (Nasdaq: IMAB) today join [ … ]
Tue, 18.08.2020
MorphoSys AG
National Comprehensive Cancer Network(R) Adds Monjuvi(R) (tafasitamab-cxix) to its Clinical Practice Guidelines in Oncology for B-cell Lymphomas
PLANEGG/MUNICH, Germany and WILMINGTON, Del. - August 18, 2020 - MorphoSys AG (FSE:MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR) and Incyte (Nasdaq:INCY) today announced that Monjuvi(R) (taf [ … ]
Wed, 05.08.2020
MorphoSys AG
Planegg/Munich, Germany, August 5, 2020
MorphoSys Reports Second Quarter and First Half
2020 Results
Conference call and webcast (in English) to be held on August 6, 2020 at 2:00pm CEST (1:00pm BST/8:00am EDT)
MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR) reports results for the second quarter and first half of [ … ]
Sat, 01.08.2020
MorphoSys AG
FDA Approves Monjuvi(R) (tafasitamab-cxix) in Combination with Lenalidomide for the Treatment of Adult Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)- First FDA approval of a second-line treatment for adult patients with relapsed or refractory DLBCL, helping fill a high unmet medical need
- FDA granted Monjuvi Fast Tra [ … ]
Thu, 30.07.2020
MorphoSys AG
Planegg/Munich, Germany, July 30, 2020
Invitation to MorphoSys' Second Quarter and First Half 2020 Results Conference Call on August 6, 2020
MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) will publish its results for the second quarter and first half of 2020 on August 5, 2020 at 10:00pm CEST (9:00pm BST; 4:00pm ED [ … ]